Q32 Bio Reports $289.6 Million in Cash, Plans 2027 Bempikibart Trial

Q32 Bio reported $289.6 million in cash and cash equivalents as of September 30, 2026. It expects the funds to support operations through topline Phase 3 results from a planned registration-directed program expected to begin in the first half of 2027, subject to regulatory discussions.